The vaccine is personalized to a patient's tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer. The new mRNA vaccine is waiting on FDA approval but has shown great promise in Phase 3 clinical trials. An experimental vaccine offers new hope to patients with melanoma, one of the most aggressive forms of skin cancer . The pharmaceutical companies Merck and Moderna released the results of a Phase 3 clinical trial that evaluated the efficacy of a personalized mRNA-based vaccine that, when combined with immunotherapy, reduced the risk of disease recurrence or death by 42 percent compared to treatment with the immunotherapy drug alone. Georgina Long, medical director of the Australian Melanoma Institute and the study's principal investigator, said in a statement that these results are "transformative" and "have the potential to make a foundational shift in how we treat patients with earlier-stage melanoma."

Moderna and Merck's personalized mRNA cancer vaccine reduced melanoma recurrence and metastasis in a Phase 3 trial. The companies plan to seek FDA approval.

Follow this section to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW? Smart Alerts: Get notified about major news as it happens. Follow this tag to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW?

These same concepts were also used to label 656 skin disease images from the Diverse Dermatology Images dataset, providing an additional external dataset with diverse skin tone representations. We review the potential applications fortheSkinCon dataset, such asprobing models, concept-based explanations, concept bottlenecks, error analysis, andslice discovery.

Accurate and timely diagnosis of multi-class skin lesions is hampered by subjective methods, inherent data imbalance in datasets like HAM10000, and the "black box" nature of Deep Learning (DL) models. This study proposes a trustworthy and highly accurate Computer-Aided Diagnosis (CAD) system to overcome these limitations. The approach utilizes Deep Convolutional Generative Adversarial Networks (DCGANs) for per class data augmentation to resolve the critical class imbalance problem. A fine-tuned ResNet-50 classifier is then trained on the augmented dataset to classify seven skin disease categories. Crucially, LIME and SHAP Explainable AI (XAI) techniques are integrated to provide transparency by confirming that predictions are based on clinically relevant features like irregular morphology. The system achieved a high overall Accuracy of 92.50 % and a Macro-AUC of 98.82 %, successfully outperforming various prior benchmarked architectures. This work successfully validates a verifiable framework that combines high performance with the essential clinical interpretability required for safe diagnostic deployment. Future research should prioritize enhancing discrimination for critical categories, such as Melanoma NOS (F1-Score is 0.8602).

The emergence of vision-language models (VLMs) has opened new possibilities for clinical reasoning and has shown promising performance in dermatological diagnosis. However, their trustworthiness and clinical utility are often limited by three major factors: (1) Data heterogeneity, where diverse datasets lack consistent diagnostic labels and clinical concept annotations; (2) Absence of grounded diagnostic rationales, leading to a scarcity of reliable reasoning supervision; and (3) Limited scalability and generalization, as models trained on small, densely annotated datasets struggle to transfer nuanced reasoning to large, sparsely-annotated ones. To address these limitations, we propose SkinR1, a novel dermatological VLM that combines deep, textbook-based reasoning with the broad generalization capabilities of reinforcement learning (RL). SkinR1 systematically resolves the key challenges through a unified, end-to-end framework. First, we design a textbook-based reasoning generator that synthesizes high-fidelity, hierarchy-aware, and differential-diagnosis (DDx)-informed trajectories, providing reliable expert-level supervision. Second, we leverage the constructed trajectories for supervised fine-tuning (SFT) empowering the model with grounded reasoning ability. Third, we develop a novel RL paradigm that, by incorporating the hierarchical structure of diseases, effectively transfers these grounded reasoning patterns to large-scale, sparse data. Extensive experiments on multiple dermatology datasets demonstrate that SkinR1 achieves superior diagnostic accuracy. The ablation study demonstrates the importance of the reasoning foundation instilled by SFT.

Large language models (LLMs) are increasingly used to extract structured information from free-text clinical records, but prior work often focuses on single tasks, limited models, and English-language reports. We evaluated 15 open-weight LLMs on pathology and radiology reports across six use cases, colorectal liver metastases, liver tumours, neurodegenerative diseases, soft-tissue tumours, melanomas, and sarcomas, at three institutes in the Netherlands, UK, and Czech Republic. Models included general-purpose and medical-specialised LLMs of various sizes, and six prompting strategies were compared: zero-shot, one-shot, few-shot, chain-of-thought, self-consistency, and prompt graph. Performance was assessed using task-appropriate metrics, with consensus rank aggregation and linear mixed-effects models quantifying variance. Top-ranked models achieved macro-average scores close to inter-rater agreement across tasks. Small-to-medium general-purpose models performed comparably to large models, while tiny and specialised models performed worse. Prompt graph and few-shot prompting improved performance by ~13%. Task-specific factors, including variable complexity and annotation variability, influenced results more than model size or prompting strategy. These findings show that open-weight LLMs can extract structured data from clinical reports across diseases, languages, and institutions, offering a scalable approach for clinical data curation.

The skin is the largest organ in the human body, and approximately a third of the total number of cancer cases are represented by skin cancers. Melanoma is the deadliest form of skin cancer, which is responsible for an overwhelming majority of skin cancer deaths. The number of melanoma deaths is expected to increase by 4.4% in 2023. Although the mortality is significant, when detected e arly, the 5-year survival rate for melanoma is over 99% (American Cancer Society, 2022). Currently, the most accurate way to diagnose melanoma is a biopsy. This is a penetrative surgical procedure that involves higher costs but also incorporates risks of developing various infectious diseases (Lakhtakia et al., 2009). Thus, the usual clinical practice of melanoma diagnosis is visual inspection using Dermoscopy by dermatologists or specially trained clinicians. This approach presents challenges, primarily due to its resource-intensive nature in terms of time and cost. This method's accuracy of melanoma diagnosis is approximately

Innate resistance to anti-PD-1 immunotherapy remains a major clinical challenge in metastatic melanoma, with the underlying molecular networks being poorly understood. To address this, we constructed a dynamic Probabilistic Boolean Network model using transcriptomic data from patient tumor biopsies to elucidate the regulatory logic governing therapy response. We then employed a reinforcement learning agent to systematically discover optimal, multi-step therapeutic interventions and used explainable artificial intelligence to mechanistically interpret the agent's control policy. The analysis revealed that a precisely timed, 4-step temporary inhibition of the lysyl oxidase like 2 protein (LOXL2) was the most effective strategy. Our explainable analysis showed that this ''hit-and-run" intervention is sufficient to erase the molecular signature driving resistance, allowing the network to self-correct without requiring sustained intervention. This study presents a novel, time-dependent therapeutic hypothesis for overcoming immunotherapy resistance and provides a powerful computational framework for identifying non-obvious intervention protocols in complex biological systems.

Early detection of melanoma has grown to be essential because it significantly improves survival rates, but automated analysis of skin lesions still remains challenging. ABCDE, which stands for Asymmetry, Border irregularity, Color variation, Diameter, and Evolving, is a well-known classification method for skin lesions, but most deep learning mechanisms treat it as a black box, as most of the human interpretable features are not explained. In this work, we propose a deep learning framework that both classifies skin lesions into categories and also quantifies scores for each ABCD feature. It simulates the evolution of these features over time in order to represent the E aspect, opening more windows for future exploration. The A, B, C, and D values are quantified particularly within this work. Moreover, this framework also visualizes ABCD feature trajectories in latent space as skin lesions evolve from benign nevuses to malignant melanoma. The experiments are conducted using the HAM10000 dataset that contains around ten thousand images of skin lesions of varying stages. In summary, the classification worked with an accuracy of around 89 percent, with melanoma AUC being 0.96, while the feature evaluation performed well in predicting asymmetry, color variation, and diameter, though border irregularity remains more difficult to model. Overall, this work provides a deep learning framework that will allow doctors to link ML diagnoses to clinically relevant criteria, thus improving our understanding of skin cancer progression. Introduction Melanoma, an aggressive form of skin cancer, is one of the leading causes of death due to skin cancer [6]. Early diagnosis is important because the 5-year survival rate exceeds 90% for early-stage melanoma, but drops below 20% for advanced stages [6]. In order to differentiate between harmful and harmless lesions, dermatologists utilize the ABCDE method. "A" stands for "asymmetry," as malignant skin lesions often appear to be uneven; "B" stands for "border irregularity," as scientists search for jagged or notched edges; "C" If a lesion displays two or more of the attributes described above, the lesion is most likely harmful melanoma.